Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;82(1):159-198.
doi: 10.1016/j.jinf.2020.05.039. Epub 2020 May 27.

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19

Elise Klement-Frutos  1 , Sonia Burrel  2 , Gilles Peytavin  3 , Stéphane Marot  4 , Minh P Lê  5 , Nagisa Godefroy  6 , Vincent Calvez  7 , Anne-Geneviève Marcelin  8 , Eric Caumes  9 , Valérie Pourcher  10 , David Boutolleau  11
Affiliations
Comment

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19

Elise Klement-Frutos et al. J Infect. 2021 Jan.
No abstract available

Keywords: Covid-19; Lopinavir; Protease inhibitor; Sars-cov-2; Virology; pharmacology.

PubMed Disclaimer

Figures

Fig 1
Fig. 1
Viral dynamics in multiple and sequential clinical samples and kinetics of lopinavir plasma concentrations in a patient with confirmed SARS-CoV-2 infection and treated with oral ritonavir boosted lopinavir. Real-time RT-PCR targeting viral E gene, presented by reverse Ct values on left vertical axis, was performed in serial different types of clinical samples collected from the patient: nasopharyngeal swab (◆), induced sputum (■), saliva (◆), plasma (▴), and stool (■). Lopinavir concentration (●), expressed in ng/mL on right vertical axis, was measured in sequential plasma samples by liquid chromatography tandem mass spectrometry method. Range of lopinavir minimal plasma concentrations: 4.660 ± 2.250 ng/mL Duration of ritonavir-boosted lopinavir (400/100 mg) treatment (D9 to D18) is indicated on the top of the graph. SARS-CoV-2 antibody response (IgG seroconversion) in indicated on the graph (D16). Undet: undetectable (Ct>50).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. WHO. Coronavirus disease (COVID-19): situation Report – 114 Data as received by WHO from national authorities by 10:00 CEST, 13 May 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
    1. Fauci A.S., Lane H.C., Redfield R.R. Covid-19 - Navigating the Uncharted. N Engl J Med. 2020;382:1268–1269. doi: 10.1056/NEJMe2002387. - DOI - PMC - PubMed
    1. Jeon S., Ko M., Lee J., Choi I., Byun S.Y., Park S., Shum D., Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv. 2020 doi: 10.1101/2020.03.20.999730. - DOI - PMC - PubMed
    1. Prajapat M., Sarma P., Shekhar N., Avti P. Drug targets for corona virus: a systematic review. Indian J Pharmacol. 2020;52(1):56–65. https://www.ncbi.nlm.nih.gov/pubmed/32201449 - PMC - PubMed
    1. Chan K.S., Lai S.T., Chu C.M. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9:399–406. https://www.ncbi.nlm.nih.gov/pubmed/14660806 - PubMed